后COVID肺部疾病的挑战和机遇:对免疫调节的集中审查
Steffi Verbeeck Mendez1, Isabella L Do Orozco2, Guadalupe E Gavilanez-Chavez3
1Facultad de Medicina, Universidad Autónoma de Guadalajara, Guadalajara 45129, Mexico.
International journal of molecular sciences
|May 7, 2025
概括
后COVID综合征 (PCS) 可能导致肺纤维化. 本综述探讨了免疫调节剂作为PCS肺部并发症的潜在治疗方法,强调了临床试验的必要性.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- 后COVID综合征 (PCS) 呈现急性和慢性疾病,包括肺部疾病.
- 后COVID-19肺纤维化 (PC19-PF) 影响高达9%的PCS患者,模仿异常性肺纤维化 (IPF).
- 对肺部PCS的有效治疗策略对于患者的治疗结果至关重要.
研究的目的:
- 审查免疫调节剂在治疗COVID后肺性综合征 (PCS) 中使用的证据.
- 评估免疫调节药物在控制PC19-PF方面的潜力.
- 识别知识上的差距,并倡导进一步的研究.
主要方法:
- 根据扩展的PRIMSA指南进行了范围审查.
- 审查重点是免疫调节剂在病毒感染和炎症状况中已知有效性.
- 文献搜索包括在COVID-19大流行期间使用免疫调节器的研究.
主要成果:
- 该综述总结了相关药物的免疫调节特性.
- 介绍了免疫调节剂对病毒感染和慢性炎症的疗效的证据.
- 讨论了COVID-19大流行期间这些药物的应用.
结论:
- 免疫调节剂显示出治疗PCS肺部并发症的潜力,包括PC19-PF.
- 进一步的精心设计的临床试验对于了解肺PCS和PC19-PF的病理学至关重要.
- 需要有效性和安全性数据来确定免疫调节剂是可行的治疗选择.
相关概念视频
Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
COPD: Pathogenesis and Clinical Features
2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K
COPD: Management Using Bronchodilators and Corticosteroids
1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Chronic Obstructive Pulmonary Disease-I: Introduction
4.0K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.0K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
5.0K
Chronic Obstructive Pulmonary Disease I: Introduction
73
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
73


